Equities Analysts Set Expectations for PRQR FY2030 Earnings

ProQR Therapeutics N.V. (NASDAQ:PRQR) – Investment analysts at HC Wainwright upped their FY2030 earnings per share estimates for shares of ProQR Therapeutics in a report issued on Monday, August 17th. HC Wainwright analyst A. Ghosh now forecasts that the biopharmaceutical company will post earnings per share of $0.20 for the year, up from their previous estimate of $0.18. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.52) per share.

Other equities research analysts also recently issued research reports about the company. Wall Street Zen raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday. Chardan Capital decreased their price target on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, June 26th. JonesTrading decreased their price target on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, June 26th. Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. Finally, Weiss Ratings raised shares of ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.33.

ProQR Therapeutics Trading Up 0.5%

PRQR opened at $1.93 on Tuesday. The firm has a market cap of $203.35 million, a price-to-earnings ratio of -4.20 and a beta of 0.07. ProQR Therapeutics has a 12 month low of $1.33 and a 12 month high of $3.10. The stock has a fifty day moving average price of $1.75 and a 200-day moving average price of $1.66.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Osaic Holdings Inc. lifted its holdings in shares of ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 4,500 shares during the period. Guggenheim Capital LLC acquired a new position in ProQR Therapeutics in the 4th quarter worth approximately $35,000. Invesco Ltd. acquired a new position in ProQR Therapeutics in the 4th quarter worth approximately $51,000. Axiom Investment Management LLC purchased a new position in ProQR Therapeutics during the 1st quarter worth approximately $53,000. Finally, Simplex Trading LLC raised its position in ProQR Therapeutics by 44,169.0% during the 4th quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company’s stock worth $89,000 after buying an additional 44,169 shares during the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Boer Daniel Anton De acquired 150,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were purchased at an average cost of $1.74 per share, with a total value of $261,000.00. Following the completion of the acquisition, the chief executive officer directly owned 300,000 shares of the company’s stock, valued at $522,000. This represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bart Filius bought 150,000 shares of the business’s stock in a transaction that occurred on Friday, July 17th. The stock was purchased at an average cost of $1.72 per share, for a total transaction of $258,000.00. Following the completion of the transaction, the director owned 300,000 shares in the company, valued at $516,000. This trade represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 600,000 shares of company stock valued at $988,500. Corporate insiders own 8.40% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.